Patent · US Active

Prodrugs of imidazotriazine compounds as CK2 inhibitors

US10550125B2 · kind B2 · utility

0Cited by

5References

5Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ashok Vinayak Purandare · Pennington, US
Kurt Zimmermann · Durham, US
Honghe Wan · Pennington, US

Key dates

Filing date	Oct 19, 2016
Grant date	Feb 4, 2020
Priority date	—
Expiry date	Oct 19, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides pharmaceutically active compounds of formula (I) and prodrugs thereof. The formula (I) 2-(aminophenylamino)-4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazine derivatives inhibit CK2 protein kinase activity, thereby making them useful for treating cancer, psoriasis and rheumatoid arthritis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.